BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

Arix Bioscience plc (LSE:ARIX) announced a series of senior management departures. CEO Joe Anderson has stepped down as CEO of the healthcare and life science investment company along with two undisclosed members of the senior...
BioCentury | Mar 28, 2019
Finance

Polyneuron’s surgical strike

Polyneuron’s broad platform and method of directly targeting autoantibodies rather than B cells for autoimmune diseases prompted Sofinnova Partners and New Enterprise Associates to invest in the Basel-based company’s CHF22.5 million ($22.6 million) series A...
BioCentury | Mar 28, 2019
Financial News

Polyneuron raises $22.6M series A to bring neuropathy therapy into clinic

Backed by Sofinnova Partners and New Enterprise Associates, Polyneuron raised CHF22.5M ($22.6 million) in a series A round to bring its anti-MAG neuropathy therapy, PN-1007, into the clinic. Polyneuron Pharmaceuticals AG (Basel, Switzerland) is developing...
BioCentury | Aug 8, 2018
Emerging Company Profile

Catching antibodies with polymers

Polyneuron Pharmaceuticals AG's glycopolymers act as decoys for the autoantibodies that drive autoimmune diseases, such as anti-MAG neuropathy, and are designed to be more effective and safer than other therapies. Polyneuron's Antibody-Catch platform generates glycopolymers...
Items per page:
1 - 4 of 4
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

Arix Bioscience plc (LSE:ARIX) announced a series of senior management departures. CEO Joe Anderson has stepped down as CEO of the healthcare and life science investment company along with two undisclosed members of the senior...
BioCentury | Mar 28, 2019
Finance

Polyneuron’s surgical strike

Polyneuron’s broad platform and method of directly targeting autoantibodies rather than B cells for autoimmune diseases prompted Sofinnova Partners and New Enterprise Associates to invest in the Basel-based company’s CHF22.5 million ($22.6 million) series A...
BioCentury | Mar 28, 2019
Financial News

Polyneuron raises $22.6M series A to bring neuropathy therapy into clinic

Backed by Sofinnova Partners and New Enterprise Associates, Polyneuron raised CHF22.5M ($22.6 million) in a series A round to bring its anti-MAG neuropathy therapy, PN-1007, into the clinic. Polyneuron Pharmaceuticals AG (Basel, Switzerland) is developing...
BioCentury | Aug 8, 2018
Emerging Company Profile

Catching antibodies with polymers

Polyneuron Pharmaceuticals AG's glycopolymers act as decoys for the autoantibodies that drive autoimmune diseases, such as anti-MAG neuropathy, and are designed to be more effective and safer than other therapies. Polyneuron's Antibody-Catch platform generates glycopolymers...
Items per page:
1 - 4 of 4